Microbiome Therapeutics Market Report: Growth Drivers, Competitive Landscape, and Outlook to 2031

QY Research has recently published a report, titled "Microbiome Therapeutics Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". The global Microbiome Therapeutics market is comprehensively analyzed in the report with the main objective of providing accurate market data and useful recommendations to help players to gain strong growth in future. The report is compiled by subject matter experts and experienced market analysts, which makes it highly authentic and reliable. Readers are provided with deep analysis of historical and future market scenarios to get sound understanding of market competition and other important aspects. The report offers exhaustive research on market dynamics, key segments, leading players, and different regional markets. It is a complete package of thorough analysis and research on the global Microbiome Therapeutics market.

The global market for Microbiome Therapeutics was estimated to be worth US$ 568 million in 2024 and is forecast to a readjusted size of US$ 3351 million by 2031 with a CAGR of 30.5% during the forecast period 2025-2031.

Get PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.in/request-sample/medical-care-microbiome-therapeutics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

As the global push for personalized medicine, chronic disease management, and immune-oncology adjunct therapies gains momentum, microbiome therapeutics is entering a critical commercialization window. Regulatory agencies such as the FDA and EMA are streamlining approval pathways for live biotherapeutic products (LBPs), while landmark approvals of Rebyota and Vowst mark a turning point. Strategic alliances between biotech startups and global pharma are accelerating late-stage clinical programs, supported by both capital and platform synergies.

Despite its transformative potential, the microbiome therapeutics sector faces multiple uncertainties. Manufacturing and regulatory frameworks remain inconsistent across countries, slowing clinical translation. Microbiota therapies face inherent variability and complexity, posing challenges in standardizing efficacy and trial design. Technical bottlenecks in sample sourcing, cold-chain logistics, and microbial viability maintenance elevate development costs. Additionally, market education and patient acceptance still require time, particularly in emerging regions like Asia, where applications are largely limited to early-stage R&D and clinical trials.

Demand is expanding beyond gastrointestinal conditions into systemic diseases such as IBD, recurrent Clostridioides difficile infection (CDI), cancer immunotherapy, Parkinson's, and autism spectrum disorders. Partnerships between CROs and pharma are intensifying, while genomics, metabolomics, and AI are enabling high-throughput microbial strain screening. The clinical sector is seeking more reproducible, orally deliverable LBPs and microbiome-derived metabolite products, which align with industrial scalability. With public and private insurers beginning to cover these new modalities, microbiome therapeutics is on the path to becoming a standard pillar of precision medicine.

Drivers and Restraints-

The report explains the drivers shaping the future of the Microbiome Therapeutics market. It evaluates the various forces that are expected to create a positive influence on the overall market. Analysts have studied the investments in research and development of products and technologies that are expected to give the players a definite boost. Furthermore, researchers have also included an analysis of the changing consumer behavior that is projected to impact the supply and demand cycles present in the global Microbiome Therapeutics market. Evolving per capita earnings, improving economic statuses, and emerging trends have all been studied in this research report.

The research report also explains the potential restraints present in the global Microbiome Therapeutics market. It evaluates the aspects that are likely to hamper the market growth in the near future. In addition to this assessment, it also provides a list of opportunities that could prove lucrative to the overall market. Analysts provide solutions for turning threats and restraints into successful opportunities in the coming years.

The competitive landscape of the global Microbiome Therapeutics market is broadly studied in the report with large focus on recent developments, future plans of top players, and key growth strategies adopted by them. The analysts authoring the report have profiled almost every major player of the global Microbiome Therapeutics market and thrown light on their crucial business aspects such as production, areas of operation, and product portfolio. All companies analyzed in the report are studied on the basis of vital factors such as market share, market growth, company size, production volume, revenue, and earnings.

Key Players Mentioned in the Global Microbiome Therapeutics Market Research Report:

Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Finch Therapeutics
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
Ferring
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Vedanta Biosciences
Metabogen

The report offers great insights into important segments of the global Microbiome Therapeutics market while concentrating on their CAGR, market size, market share, and future growth potential. The global Microbiome Therapeutics market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Microbiome Therapeutics market.

Details of Microbiome Therapeutics Market Segmentation: -

Segment by Type:

Upper GIT
Lower GIT

Segment by Application:

C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others

Research Methodology

This report has been compiled using latest primary and secondary research methodologies such as data triangulation, qualitative and quantitative analysis, and top-down and bottom-up approaches. The researchers also referred to reliable secondary sources for collecting important data and statistics. All the findings of the research study have been verified and revalidated with the help of authentic primary sources.

The researchers create a unique model and customize it for each research study. Their market forecasts are based on the industry-best combination of domain expertise, industry knowledge and experience, technological analysis, and economic tools. Technological market models are generally adopted for long-term market forecasting, whereas econometric models are adopted for short-term forecasting. The researchers were provided with advanced analysis tools at the time of the preparation of the report.

Report Objectives

(1) To carefully analyze and estimate the size of the global Microbiome Therapeutics market

(2) To clearly segment the global Microbiome Therapeutics market and estimate the market size of the segments

(3) To provide details about key strategies adopted by leading players of the global Microbiome Therapeutics market

(4) To help readers understand current and future market scenarios

(5) To provide information about latest trends of the global Microbiome Therapeutics market and its key segments

(6) To assess the contribution of each region or country to the global Microbiome Therapeutics market

(7) To provide information on important drivers, restraints, and opportunities of the global Microbiome Therapeutics market

(8) To accurately calculate the market shares of key segments, regions, and companies in the global Microbiome Therapeutics market

Request Pre-Order Enquiry or Customized Research on This Report: https://www.qyresearch.in/pre-order-inquiry/medical-care-microbiome-therapeutics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Content

1 Market Overview
1.1 Microbiome Therapeutics Product Introduction
1.2 Global Microbiome Therapeutics Market Size Forecast (2020-2031)
1.3 Microbiome Therapeutics Market Trends & Drivers
1.3.1 Microbiome Therapeutics Industry Trends
1.3.2 Microbiome Therapeutics Market Drivers & Opportunity
1.3.3 Microbiome Therapeutics Market Challenges
1.3.4 Microbiome Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Microbiome Therapeutics Players Revenue Ranking (2024)
2.2 Global Microbiome Therapeutics Revenue by Company (2020-2025)
2.3 Key Companies Microbiome Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Microbiome Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Microbiome Therapeutics
2.6 Microbiome Therapeutics Market Competitive Analysis
2.6.1 Microbiome Therapeutics Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Microbiome Therapeutics Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Microbiome Therapeutics as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Upper GIT
3.1.2 Lower GIT
3.2 Global Microbiome Therapeutics Sales Value by Type
3.2.1 Global Microbiome Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Microbiome Therapeutics Sales Value, by Type (2020-2031)
3.2.3 Global Microbiome Therapeutics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 C. difficile Infection (CDI)
4.1.2 Inflammatory Bowel Disease (IBD)
4.1.3 Orphan Drug
4.1.4 Immuno-oncology
4.1.5 Others
4.2 Global Microbiome Therapeutics Sales Value by Application
4.2.1 Global Microbiome Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Microbiome Therapeutics Sales Value, by Application (2020-2031)
4.2.3 Global Microbiome Therapeutics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Microbiome Therapeutics Sales Value by Region
5.1.1 Global Microbiome Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Microbiome Therapeutics Sales Value by Region (2020-2025)
5.1.3 Global Microbiome Therapeutics Sales Value by Region (2026-2031)
5.1.4 Global Microbiome Therapeutics Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Microbiome Therapeutics Sales Value, 2020-2031
5.2.2 North America Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Microbiome Therapeutics Sales Value, 2020-2031
5.3.2 Europe Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Microbiome Therapeutics Sales Value, 2020-2031
5.4.2 Asia Pacific Microbiome Therapeutics Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Microbiome Therapeutics Sales Value, 2020-2031
5.5.2 South America Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Microbiome Therapeutics Sales Value, 2020-2031
5.6.2 Middle East & Africa Microbiome Therapeutics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Microbiome Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Microbiome Therapeutics Sales Value, 2020-2031
6.3 United States
6.3.1 United States Microbiome Therapeutics Sales Value, 2020-2031
6.3.2 United States Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Microbiome Therapeutics Sales Value, 2020-2031
6.4.2 Europe Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Microbiome Therapeutics Sales Value, 2020-2031
6.5.2 China Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
6.5.3 China Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Microbiome Therapeutics Sales Value, 2020-2031
6.6.2 Japan Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Microbiome Therapeutics Sales Value, 2020-2031
6.7.2 South Korea Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Microbiome Therapeutics Sales Value, 2020-2031
6.8.2 Southeast Asia Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Microbiome Therapeutics Sales Value, 2020-2031
6.9.2 India Microbiome Therapeutics Sales Value by Type (%), 2024 VS 2031
6.9.3 India Microbiome Therapeutics Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Seres Therapeutics
7.1.1 Seres Therapeutics Profile
7.1.2 Seres Therapeutics Main Business
7.1.3 Seres Therapeutics Microbiome Therapeutics Products, Services and Solutions
7.1.4 Seres Therapeutics Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.1.5 Seres Therapeutics Recent Developments
7.2 Assembly Biosciences
7.2.1 Assembly Biosciences Profile
7.2.2 Assembly Biosciences Main Business
7.2.3 Assembly Biosciences Microbiome Therapeutics Products, Services and Solutions
7.2.4 Assembly Biosciences Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.2.5 Assembly Biosciences Recent Developments
7.3 Synthetic Biologics
7.3.1 Synthetic Biologics Profile
7.3.2 Synthetic Biologics Main Business
7.3.3 Synthetic Biologics Microbiome Therapeutics Products, Services and Solutions
7.3.4 Synthetic Biologics Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.3.5 Synthetic Biologics Recent Developments
7.4 Finch Therapeutics
7.4.1 Finch Therapeutics Profile
7.4.2 Finch Therapeutics Main Business
7.4.3 Finch Therapeutics Microbiome Therapeutics Products, Services and Solutions
7.4.4 Finch Therapeutics Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.4.5 Finch Therapeutics Recent Developments
7.5 PureTech
7.5.1 PureTech Profile
7.5.2 PureTech Main Business
7.5.3 PureTech Microbiome Therapeutics Products, Services and Solutions
7.5.4 PureTech Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.5.5 PureTech Recent Developments
7.6 Synlogic
7.6.1 Synlogic Profile
7.6.2 Synlogic Main Business
7.6.3 Synlogic Microbiome Therapeutics Products, Services and Solutions
7.6.4 Synlogic Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.6.5 Synlogic Recent Developments
7.7 Enterome BioScience
7.7.1 Enterome BioScience Profile
7.7.2 Enterome BioScience Main Business
7.7.3 Enterome BioScience Microbiome Therapeutics Products, Services and Solutions
7.7.4 Enterome BioScience Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.7.5 Enterome BioScience Recent Developments
7.8 4D Pharma
7.8.1 4D Pharma Profile
7.8.2 4D Pharma Main Business
7.8.3 4D Pharma Microbiome Therapeutics Products, Services and Solutions
7.8.4 4D Pharma Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.8.5 4D Pharma Recent Developments
7.9 Second Genome
7.9.1 Second Genome Profile
7.9.2 Second Genome Main Business
7.9.3 Second Genome Microbiome Therapeutics Products, Services and Solutions
7.9.4 Second Genome Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.9.5 Second Genome Recent Developments
7.10 Ferring
7.10.1 Ferring Profile
7.10.2 Ferring Main Business
7.10.3 Ferring Microbiome Therapeutics Products, Services and Solutions
7.10.4 Ferring Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.10.5 Ferring Recent Developments
7.11 C3 Jian
7.11.1 C3 Jian Profile
7.11.2 C3 Jian Main Business
7.11.3 C3 Jian Microbiome Therapeutics Products, Services and Solutions
7.11.4 C3 Jian Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.11.5 C3 Jian Recent Developments
7.12 Rebiotix
7.12.1 Rebiotix Profile
7.12.2 Rebiotix Main Business
7.12.3 Rebiotix Microbiome Therapeutics Products, Services and Solutions
7.12.4 Rebiotix Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.12.5 Rebiotix Recent Developments
7.13 MicroBiome Therapeutics LLC
7.13.1 MicroBiome Therapeutics LLC Profile
7.13.2 MicroBiome Therapeutics LLC Main Business
7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Products, Services and Solutions
7.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.13.5 MicroBiome Therapeutics LLC Recent Developments
7.14 Metabiomics
7.14.1 Metabiomics Profile
7.14.2 Metabiomics Main Business
7.14.3 Metabiomics Microbiome Therapeutics Products, Services and Solutions
7.14.4 Metabiomics Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.14.5 Metabiomics Recent Developments
7.15 Ritter Pharmaceuticals
7.15.1 Ritter Pharmaceuticals Profile
7.15.2 Ritter Pharmaceuticals Main Business
7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Products, Services and Solutions
7.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.15.5 Ritter Pharmaceuticals Recent Developments
7.16 Symberix
7.16.1 Symberix Profile
7.16.2 Symberix Main Business
7.16.3 Symberix Microbiome Therapeutics Products, Services and Solutions
7.16.4 Symberix Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.16.5 Symberix Recent Developments
7.17 OpenBiome
7.17.1 OpenBiome Profile
7.17.2 OpenBiome Main Business
7.17.3 OpenBiome Microbiome Therapeutics Products, Services and Solutions
7.17.4 OpenBiome Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.17.5 OpenBiome Recent Developments
7.18 Azitra
7.18.1 Azitra Profile
7.18.2 Azitra Main Business
7.18.3 Azitra Microbiome Therapeutics Products, Services and Solutions
7.18.4 Azitra Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.18.5 Azitra Recent Developments
7.19 Symbiotix Biotherapies
7.19.1 Symbiotix Biotherapies Profile
7.19.2 Symbiotix Biotherapies Main Business
7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Products, Services and Solutions
7.19.4 Symbiotix Biotherapies Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.19.5 Symbiotix Biotherapies Recent Developments
7.20 Vedanta Biosciences
7.20.1 Vedanta Biosciences Profile
7.20.2 Vedanta Biosciences Main Business
7.20.3 Vedanta Biosciences Microbiome Therapeutics Products, Services and Solutions
7.20.4 Vedanta Biosciences Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.20.5 Vedanta Biosciences Recent Developments
7.21 Metabogen
7.21.1 Metabogen Profile
7.21.2 Metabogen Main Business
7.21.3 Metabogen Microbiome Therapeutics Products, Services and Solutions
7.21.4 Metabogen Microbiome Therapeutics Revenue (US$ Million) & (2020-2025)
7.21.5 Metabogen Recent Developments
8 Industry Chain Analysis
8.1 Microbiome Therapeutics Industrial Chain
8.2 Microbiome Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Microbiome Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Microbiome Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

Contact US

Ankit Jain - Director, Global Digital Marketing

QY Research, INC.
India Office -
315Work Avenue, Raheja Woods, Kalyani Nagar,
Pune, Maharashtra 411006, India
Web - https://www.qyresearch.in
Email- ankit@qyresearch.com

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 17 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

This release was published on openPR.